Not Approved (US) Longevity & Mitochondrial

Prostamax

also known as: Prostagen, Prostate peptide bioregulator, KEDP tetrapeptide

A Khavinson prostate bioregulator preparation marketed in Russia for prostate aging, with the synthetic KEDP tetrapeptide (Prostagen) as its characterized active fragment. Russian-language evidence base; no FDA/EMA status; no independent Western clinical replication.

A prostate-tissue-derived peptide bioregulator preparation in the Khavinson cytomedine series. The associated synthetic tetrapeptide is Lys-Glu-Asp-Pro (KEDP), variously marketed under the name Prostagen, claimed in Khavinson-group studies to modulate prostate-tissue gene expression and support benign prostate aging. As with the rest of the Khavinson short-peptide series, the evidence base consists of Russian-language studies from a single research network, and mechanistic claims should be regarded as preliminary.

Mechanism of action

Proposed to modulate prostate-tissue gene expression in a "tissue-specific" Khavinson-framework manner. Mechanistic claims have not been independently validated in peer-reviewed Western literature. Speculative at the molecular level.

Primary uses

Benign prostatic aging support (Russian nutraceutical positioning)
Post-prostatitis recovery support (Russian clinical use)

Typical dosing

1–2 capsules 1–2 times daily in 20–30 day courses (oral)

Russian nutraceutical dosing. No controlled clinical evidence of efficacy.

Regulatory status

Not FDA- or EMA-approved. Sold in Russia and CIS markets as a nutraceutical supplement; the synthetic KEDP tetrapeptide (Prostagen) is sold as a research chemical in grey-market catalogs. No registered-medicine status in any Western jurisdiction.

References

[review] Khavinson VK, et al. "Tetrapeptide Prostamax stimulates gene expression and protein synthesis in prostate tissue." Bull Exp Biol Med, 2010;149:354-356.
[review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Testagen

A Khavinson testis bioregulator preparation — note that the synthetic tetrapeptide KEDG has been reported in different Khavinson-group publications under both the Testagen and Ventfort names, reflecting either genuine tissue-source overlap or inconsistent nomenclature in the primary literature. Evidence is Russian-language; Russian nutraceutical status only.

Pinealon

A Khavinson tripeptide proposed to cross the blood–brain barrier and support neuronal gene expression in aging brain tissue — animal data in hypoxia and oxidative stress models; no Western clinical trials.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.